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1. INTRODUCTION {#dom12957-sec-0005}
===============

Many patients with type 2 diabetes mellitus (T2DM) have progressive β‐cell failure that ultimately requires the use of insulin as part of their treatment regimen.[1](#dom12957-bib-0001){ref-type="ref"}, [2](#dom12957-bib-0002){ref-type="ref"}, [3](#dom12957-bib-0003){ref-type="ref"} Current treatment guidelines recommend continuation of oral antidiabetic drugs in patients being transitioned to insulin,[4](#dom12957-bib-0004){ref-type="ref"} and nearly all oral antidiabetic drugs, including metformin, sulphonylurea and dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have been combined effectively with insulin.[5](#dom12957-bib-0005){ref-type="ref"}, [6](#dom12957-bib-0006){ref-type="ref"}, [7](#dom12957-bib-0007){ref-type="ref"}

Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors are the newest class of oral antidiabetic drug and have several important characteristics that make them attractive for use in combination with insulin.[8](#dom12957-bib-0008){ref-type="ref"} These drugs lower plasma glucose levels by increasing urinary excretion.[8](#dom12957-bib-0008){ref-type="ref"}, [9](#dom12957-bib-0009){ref-type="ref"} Their mechanism of action is independent of insulin and their glucose‐lowering effects should be expected to complement those of insulin therapy.[8](#dom12957-bib-0008){ref-type="ref"} SGLT2 inhibitors also promote weight loss and reduce blood pressure and are associated with a relatively low risk of hypoglycaemia.[8](#dom12957-bib-0008){ref-type="ref"}, [9](#dom12957-bib-0009){ref-type="ref"} The American Diabetes Association guidelines state that adjunctive use of SGLT2 inhibitors may improve glycaemic control and reduce the amount of insulin needed in patients with T2DM[4](#dom12957-bib-0004){ref-type="ref"}; however, the combination of SGLT2 inhibitors with insulin or sulphonylurea treatment may lead to increases in hypoglycaemia.[10](#dom12957-bib-0010){ref-type="ref"}, [11](#dom12957-bib-0011){ref-type="ref"}

Tofogliflozin, a highly selective SGLT2 inhibitor, has been approved in Japan for the treatment of T2DM.[12](#dom12957-bib-0012){ref-type="ref"} Clinical trials have shown that tofogliflozin, when used as monotherapy or in combination with oral antidiabetic agents, significantly decreases glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight and systolic and diastolic blood pressure (BP) in patients with T2DM, while maintaining a low risk of hypoglycaemia.[13](#dom12957-bib-0013){ref-type="ref"}, [14](#dom12957-bib-0014){ref-type="ref"}

At present, there is no information about the efficacy and safety of tofogliflozin when added to insulin therapy in patients with T2DM. The aim of the present study was to assess the effects of tofogliflozin vs placebo on glycaemic control when added to insulin treatment in terms of HbA1c reduction in patients with T2DM.

2. MATERIALS AND METHODS {#dom12957-sec-0006}
========================

2.1. Study design {#dom12957-sec-0007}
-----------------

This was a 16‐week, randomized, double‐blind, placebo‐controlled multicentre trial that also included a 36‐week extension period (NCT02201004). The study was conducted in 30 diabetes outpatient clinics in Japan. During the 16‐week double‐blind treatment period, patients with T2DM inadequately controlled on insulin were assigned randomly 2:1 to tofogliflozin 20 mg or placebo once daily (before or after breakfast). Randomization was stratified based on a minimization method including HbA1c level (\<8.0% and ≥8.0%), insulin regimen (basal‐bolus, bolus, premix, basal) and estimated glomerular filtration rate (eGFR; ≥90, ≥60 to \<90, ≥30 to \<60 mL/min/1.73 m^2^) and was conducted via an interactive web response system (IWRS).

The 16‐week double‐blind treatment period was followed by a 36‐week open‐label extension in which all patients received 20 mg/d tofogliflozin. The primary endpoints during the double‐blind treatment period were efficacy and safety and that for the open‐label extension was safety. Patients were dispensed their allotted medication at each study visit according to the treatment numbers provided by the IWRS. Tofogliflozin and placebo containers were visually indistinguishable.

The trial was conducted in accordance with the principles in the protocol and in Article 14.4.4, 14.4.7 of the Japanese Pharmaceutical Affairs Act, the Good Clinical Practice Standards for the Implementation of Clinical Trials (Ordinance of the Pharmaceutical Affairs Bureau, Ministry of Health and Welfare No. 28 of March 1997), the Good Post‐Marketing Study Practice (Ordinance of the Japanese Pharmaceutical Affairs Bureau, Ministry of Health, Labour and Welfare No.171 of 20 December 2004) and related notices. The study protocol was also approved by local institutional review boards. All patients provided informed written consent.

2.2. Participant inclusion and exclusion criteria {#dom12957-sec-0008}
-------------------------------------------------

Patients presenting at the diabetes outpatient clinics of the participating investigators were eligible for participation. Participating investigators screened patients for eligibility and entered them into the randomization sequence.

The trial included men and women (aged ≥20 to ≤75 years) with T2DM inadequately controlled on insulin monotherapy or on combination of basal insulin and a DPP‐4 inhibitor. Patients were treated for ≥3 months prior to screening with stable insulin doses (±20%) in basal‐bolus, bolus, premix (low and high) or basal regimens. At screening, patients had HbA1c concentrations between 7.5% and 10.5% (inclusive), FPG levels ≤220 mg/dL and body mass index (BMI) between 18.5 and 35.0 kg/m^2^. No change in DPP‐4 inhibitor dose was permitted during the 3 months before screening.

Potential patients were excluded if they had: type 1 diabetes mellitus; unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular oedema; history of metabolic acidosis ≤1 year prior to screening visit; severe uncontrolled hyperglycaemia; history of drug or alcohol abuse; transient ischaemic attacks; or acute cerebrovascular or cardiovascular events requiring hospitalization ≤6 months prior to screening. Severe or uncontrolled congestive heart failure, initiation of weight loss drugs ≤3 months prior to screening, use of systemic glucocorticoids for a total of 1 week or more within 3 months prior to screening visit, and use of any investigational drugs within 3 months prior to the screening visit were also grounds for exclusion. Potential patients were also excluded if they had haemoglobinopathy or haemolytic anaemia, had received blood or plasma products within 3 months prior to screening visit, or required dosing changes within 4 weeks before screening for lipid‐lowering, antihypertensive or uric acid‐lowering drugs, or for a thyroid hormone preparation. Blood pressure \>180/110 mm Hg, alanine aminotransferase or alanine aminotransferase levels \>3.0 times the upper limit of the reference range (× ULN), total bilirubin \>1.5 × ULN, elevated serum creatinine (2.0 mg/dL for men, 1.5 mg/dL for women), evidence of hepatitis B or C virus infection, a positive serum pregnancy test result, severe renal impairment (eGFR \<30 mL/min/1.73 m^2^ and/or on dialysis), serious infection, abnormal pituitary or adrenal function, and urinary tract or genital infections were also grounds for exclusion.

2.3. Insulin dosing {#dom12957-sec-0009}
-------------------

The insulin dose was not to be changed during the 16‐week double‐blind treatment period unless the patient experienced hypoglycaemia. The insulin dose could only be reduced if hypoglycaemia occurred or to prevent the occurrence of this adverse event (AE). The insulin dose changed if FPG was ≥240 mg/dL and did not decrease to below 240 mg/dL with appropriate treatment during the 16‐week period (defined as rescue therapy).

2.4. Study endpoints {#dom12957-sec-0010}
--------------------

### 2.4.1. Efficacy {#dom12957-sec-0011}

The primary endpoint was the change from baseline to 16 weeks in HbA1c for tofogliflozin vs placebo. Secondary endpoints included comparison of the changes from baseline to week 16 for tofogliflozin vs placebo in FPG, postprandial plasma glucose (PPG; glucose level measured 2 hours after standardized breakfast at weeks 0 and 16), body weight, systolic and diastolic BP, uric acid, lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) and insulin dose. The between‐group differences in the proportions of patients who achieved HbA1c \<7.0% or ≤6.5% at week 16 were also determined.

### 2.4.2. Safety {#dom12957-sec-0012}

Hypoglycaemic episodes were assessed by patient diary entries, which were reviewed at each study visit. Hypoglycaemia was classified as severe, documented symptomatic, asymptomatic, probable symptomatic or nocturnal; see File [S1](#dom12957-supitem-0001){ref-type="supplementary-material"} for definitions of these classifications. AE data (treatment‐emergent AEs \[TEAEs\] and serious AEs \[SAEs\]) and vital signs were collected at each study visit. Urinary tract or genital infections were recorded based on diagnosis by the investigator. Clinical laboratory tests were performed at randomization and at the final visit in the double‐blind period (week 16).

2.5. Statistical analyses {#dom12957-sec-0013}
-------------------------

Efficacy was assessed in the modified intention‐to‐treat (mITT) population, which included patients randomized and exposed to at least 1 dose of tofogliflozin or placebo who had both a baseline measurement and at least 1 post‐baseline measurement for any efficacy variable.

Efficacy variables compared with placebo including the primary endpoint were analysed using a mixed model with repeated measurements (MMRM), with treatment group, visit, treatment group‐by‐visit interaction, randomization strata of screening HbA1c, insulin regimen and eGFR as fixed effects, and baseline HbA1c and baseline HbA1c‐by‐visit interaction as covariates. The least squares (LS) mean changes in each variable from baseline to week 16 for each treatment group were provided in the framework of this model, as well as the difference between treatment groups and the 95% confidence interval (CI) for the LS mean. Statistical tests for efficacy variables had a 2‐sided 5% significance level.

For the primary efficacy endpoint, sensitivity analyses were performed with imputed value by method of last observation carried forward (LOCF) by means of analysis of covariance and including data collected after rescue therapy using the MMRM model. Subgroup analyses were also performed using the MMRM model.

Responder rates for HbA1c \<7.0% and ≤6.5% at week 16 in the two treatment groups were compared using a Cochran--Mantel--Haenszel test, stratified as described above, and both *P* values and 95% CIs were determined.

All safety analyses were performed on the safety population, which was defined as all patients randomized and exposed to at least one dose of study treatment.

### 2.5.1. Sample size determination {#dom12957-sec-0014}

A sample size of 128 patients for the tofogliflozin group and 64 for the placebo group with a 2:1 allocation rate was calculated as sufficient to detect a between‐group difference of 0.5% in the absolute change in HbA1c from baseline to week 16 with a power of 90%. This assumed a common standard deviation of 1.0% at a two‐sided 5% significance level. Considering dropout, a total of 210 randomized patients (140 tofogliflozin, 70 placebo) was determined to be necessary.

3. RESULTS {#dom12957-sec-0015}
==========

3.1. Patients {#dom12957-sec-0016}
-------------

A total of 320 patients were screened and 211 were randomized (141 tofogliflozin, 70 placebo). One patient in the tofogliflozin group underwent randomization but was not treated. The other 210 treated patients received treatment as per randomization and were included in the mITT population (Figure [1](#dom12957-fig-0001){ref-type="fig"}). The first patient enrolled in the study on June 30, 2014 and the final patient completed the 16‐week phase on January 27, 2016. Three patients discontinued tofogliflozin (2 because of AEs and 1 because of the patient\'s decision), whereas 2 discontinued placebo (1 because of the patient\'s decision and 1 because of failure to meet the entry criteria).

![Patient disposition](DOM-19-1397-g001){#dom12957-fig-0001}

There were minor differences between treatment groups with respect to several characteristics. Most notably, patients in the tofogliflozin group were older, were more likely to have existing cardiac disorders and had a longer mean duration of disease compared with those who received placebo (Table [1](#dom12957-tbl-0001){ref-type="table-wrap"}).

###### 

Baseline demographic and clinical characteristics

  Characteristics                                                                Tofogliflozin (n = 141)   Placebo (n = 70)
  ------------------------------------------------------------------------------ ------------------------- ------------------
  Age, years                                                                     59.1 ± 10.8               56.4 ± 10.0
  ≥65 years, n (%)                                                               59 (41.8)                 17 (24.3)
  Male, n (%)                                                                    90 (63.8)                 48 (68.6)
  HbA1c, %                                                                       8.53 ± 0.75               8.40 ± 0.65
  HbA1c ≥8.0%, n (%)                                                             107 (75.9)                50 (71.4)
  eGFR, mL/min/1.73 m^2^                                                         79.7 ± 19.8               79.5 ± 17.0
  eGFR ≥30 to \<60 mL/min/1.73 m^2^, n (%)                                       14 (9.9)                  9 (12.9)
  Body weight, kg                                                                68.87 ± 13.20             72.24 ± 11.12
  BMI, kg/m^2^                                                                   25.8 ± 3.5                26.9 ± 3.9
  BMI, n (%)                                                                                               
  \<25 kg/m^2^                                                                   61 (43.3)                 24 (34.3)
  ≥25 to \<30 kg/m^2^                                                            62 (44.0)                 29 (41.4)
  ≥30 kg/m^2^                                                                    18 (12.8)                 17 (24.3)
  FPG, mg/dL                                                                     163.4 ± 47.5              162.4 ± 43.2
  PPG, mg/dL                                                                     299.9 ± 68.5              302.6 ± 65.6
  Duration of diabetes, years                                                    15.02 ± 9.36              12.39 ± 7.34
  Insulin treatment*,* n (%)                                                                               
  Basal‐bolus                                                                    34 (24.1)                 17 (24.3)
  Bolus                                                                          16 (11.3)                 8 (11.4)
  Premix                                                                         23 (16.3)                 11 (15.7)
  Basal                                                                          68 (48.2)                 34 (48.6)
  Basal only                                                                     34 (24.1)                 9 (12.9)
  Basal combined with DPP‐4 inhibitors                                           34 (24.1)                 25 (35.7)
  Comorbidity                                                                                              
  Diabetic retinopathy                                                           67 (47.5)                 34 (48.6)
  Diabetic sensory or motor neuropathy[a](#dom12957-note-0003){ref-type="fn"}    41 (29.1)                 13 (18.6)
  Diabetic autonomic neuropathy[a](#dom12957-note-0003){ref-type="fn"}           9 (6.4)                   0
  Diabetic nephropathy[a](#dom12957-note-0003){ref-type="fn"}                    63 (44.7)                 27 (38.6)
  Cardiac disorders[b](#dom12957-note-0004){ref-type="fn"}                       21 (15.0)                 7 (10.0)
  Concomitant cardiovascular medication[b](#dom12957-note-0004){ref-type="fn"}                             
  β‐blocking agents                                                              11 (7.9)                  10 (14.3)
  Diuretics                                                                      10 (7.1)                  4 (5.7)
  Agents acting on the renin‐angiotensin system                                  5 (3.6)                   8 (11.4)
  Lipid‐modifying agents                                                         5 (3.6)                   5 (7.1)
  Peripheral vasodilators                                                        1 (0.7)                   1 (1.4)
  Vasoprotectives                                                                1 (0.7)                   1 (1.4)

Data are mean ± standard deviation, unless indicated otherwise.

As reported by the attending physician.

n = 140.

None of the patients who received tofogliflozin and 2 (2.9%) who were treated with placebo required rescue therapy.

3.2. Efficacy {#dom12957-sec-0017}
-------------

### 3.2.1. Primary endpoint {#dom12957-sec-0018}

Treatment with tofogliflozin resulted in a statistically significant decrease in HbA1c from baseline to week 16 compared with placebo (LS mean difference of −1.07%; *P* \< .0001; Figure [2](#dom12957-fig-0002){ref-type="fig"} and Table [2](#dom12957-tbl-0002){ref-type="table-wrap"}). The changes from baseline were −0.59% for tofogliflozin and +0.48% for placebo.

![Change in HbA1c values for tofogliflozin and placebo from baseline to week 16. Values shown are mean ± standard error](DOM-19-1397-g002){#dom12957-fig-0002}

###### 

Results for primary and secondary efficacy endpoints

                                                               Tofogliflozin   Placebo   Estimated placebo vs tofogliflozin difference                                                          
  -------------------------- --------------------------------- --------------- --------- ----------------------------------------------- ----- ------- ------- --------------- ---------------- ---------
  HbA1c, %                   Baseline                          140             8.53      0.76                                            70    8.40    0.65    --              --               --
                             Week 16                           135             7.80      0.85                                            66    8.74    0.91                                     
                             Change from baseline to week 16   135             −0.72     0.71                                            66    0.35    0.74                                     
                             LS mean                           135             −0.59     0.069                                           135   0.48    0.089   −1.07 (0.090)   −1.246, −0.890   \<.0001
  FPG, mg/dL                 Baseline                          140             164.0     47.2                                            70    162.4   43.2    −32.1 (4.37)    −40.69, −23.44   \<.0001
                             Week 16                           135             134.7     30.0                                            66    165.8   46.4                                     
                             Change from baseline to week 16   135             −27.2     38.4                                            66    5.3     41.9                                     
  PPG, mg/dL                 Baseline                          140             300.3     68.6                                            70    302.6   65.6    −67.7 (7.80)    −83.04, −52.27   \<.0001
                             Week 16                           134             236.4     61.9                                            66    302.1   74.6                                     
                             Change from baseline to week 16   134             −65.0     55.1                                            66    3.2     64.3                                     
  Body weight, kg            Baseline                          140             68.84     13.24                                           70    72.24   11.12   −1.40 (0.229)   −1.847, −0.943   \<.0001
                             Week 16                           135             67.41     13.02                                           66    72.42   11.65                                    
                             Change from baseline to week 16   135             −1.34     1.62                                            66    0.03    1.36                                     
  Systolic BP, mm Hg         Baseline                          140             134.8     16.4                                            70    134.7   15.9    −2.2 (1.93)     −5.99, 1.63      .2605
                             Week 16                           135             130.1     17.2                                            66    132.2   16.6                                     
                             Change from baseline to week 16   135             −4.8      15.0                                            66    −2.7    11.8                                     
  Diastolic BP, mm Hg        Baseline                          140             76.4      10.5                                            70    77.9    11.0    −2.9 (1.26)     −5.38, −0.43     .0218
                             Week 16                           135             74.5      11.7                                            66    78.6    10.4                                     
                             Change from baseline to week 16   135             −1.8      9.4                                             66    0.4     7.7                                      
  Uric acid, mg/dL           Baseline                          140             5.05      1.25                                            70    5.23    1.42    −0.29 (0.105)   −0.500, −0.084   .0062
                             Week 16                           135             4.87      1.24                                            66    5.27    1.44                                     
                             Change from baseline to week 16   135             −0.18     0.74                                            66    0.07    0.73                                     
  Total cholesterol, mg/dL   Baseline                          140             203.3     40.5                                            70    204.9   32.4    1.80 (3.51)     −5.10, 8.73      .6056
                             Week 16                           135             206.7     35.8                                            66    204.7   31.4                                     
                             Change from baseline to week 16   135             3.6       27.4                                            66    2.2     24.4                                     
  HDL cholesterol, mg/dL     Baseline                          140             57.0      17.0                                            70    55.6    13.9    2.7 (1.38)      −0.07, 5.37      .0559
                             Week 16                           135             59.7      18.8                                            66    56.3    14.2                                     
                             Change from baseline to week 16   135             2.9       9.0                                             66    0.3     9.6                                      
  LDL cholesterol, mg/dL     Baseline                          140             121.4     33.0                                            70    130.2   26.9    1.6 (2.99)      −4.25, 7.54      .5822
                             Week 16                           135             125.6     32.8                                            66    129.5   26.8                                     
                             Change from baseline to week 16   135             4.1       22.2                                            66    1.1     17.7                                     
  Triglycerides, mg/dL       Baseline                          140             177.0     218.9                                           70    128.6   65.6    10.1 (14.78)    −19.02, 39.29    .4938
                             Week 16                           135             145.6     111.9                                           66    124.5   78.1                                     
                             Change from baseline to week 16   135             −31.1     214.2                                           66    3.9     60.6                                     
  Insulin dose, U            Baseline                          140             26.7      17.7                                            70    28.5    19.4    −1.3 (0.52)     −2.31, −0.25     .0152
                             Week 16                           128             25.5      15.9                                            64    28.7    19.1                                     
                             Change from baseline to Week 16   128             −1.3      4.8                                             64    −0.2    0.8                                      

Abbreviations: s.d., standard deviation; s.e., standard error.

The sensitivity analysis using LOCF and excluding measurements after administration of rescue medication also indicated significant superiority of tofogliflozin over placebo for reduction of HbA1c (LS mean difference of −1.05; *P* \< .0001). This was also the case for analysis of results after receipt of rescue medication (LS mean difference of −1.09; *P* \< .0001).

Subgroup analyses indicated that addition of tofogliflozin to insulin was significantly superior to placebo in patients aged \<65 or ≥65 years (LS mean differences of −1.14 and −0.90, respectively, both *P* \< .0001); men and women (LS mean differences of −1.10 and −1.01, respectively, both *P* \< .0001); patients with baseline BMI \<25 kg/m^2^, ≥25 to \<30 kg/m^2^ and ≥30 kg/m^2^ (LS mean differences of −1.01, −0.89, and −1.50, respectively; all *P* \< .0001); and those with baseline HbA1c \<8.0% or ≥8.0% (LS mean differences of −1.10 and −1.05, respectively; both *P* \< .0001). Addition of tofogliflozin was also significantly superior to placebo in decreasing HbA1c in patients receiving basal‐bolus insulin (LS mean difference of −1.35; *P* \< .0001), bolus insulin (LS mean difference of −1.29; *P* = .0002), premix (LS mean difference of −1.00, respectively; *P* = .0005) or basal insulin (LS mean difference of −1.06; *P* \< .0001), and in patients with eGFR ≥90 mL/min/1.73 m^2^ (LS mean difference of −1.25; *P* \< .0001), ≥60 to \<90 mL/min/1.73 m^2^ (LS mean difference of −0.93; *P* \< .0001) and ≥30 to \<60 mL/min/1.73 m^2^ (LS mean difference of −1.39; *P* = .0014).

### 3.2.2. Secondary endpoints {#dom12957-sec-0019}

Small percentages of patients in each group achieved HbA1c goals at the end of 16 weeks. For tofogliflozin, 17 patients (12.1%) achieved HbA1c \<7.0% and 6 (4.3%) achieved HbA1c ≤6.5%. The respective values for placebo were 1 (1.4%; *P* = .0075) and 0 (0%; *P* = .0091).

Tofogliflozin was also significantly superior to placebo for most other secondary endpoints, including body weight (LS mean difference −1.40 kg; *P* \< .0001), FPG (LS mean difference −32.1 mg/dL; *P* \< .0001), PPG (LS mean difference −67.7 mg/dL; *P* \< .0001), diastolic BP (LS mean difference −2.9 mm Hg; *P* = .0218) and uric acid (LS mean difference −0.29 mg/dL; *P* = .0062).

3.3. Safety {#dom12957-sec-0020}
-----------

### 3.3.1. AEs {#dom12957-sec-0021}

Most patients in both treatment groups experienced ≥1 TEAE (Table [3](#dom12957-tbl-0003){ref-type="table-wrap"}). There were no deaths in either treatment group and 1 patient in each group had an SAE considered to be possibly related to study treatment. The most common TEAEs were hypoglycaemia (43 patients \[30.7%\] for tofogliflozin and 15 patients \[21.4%\] for placebo) and nasopharyngitis (13 patients \[9.3%\] for tofogliflozin and 9 patients \[12.9%\] for placebo). Two patients treated with tofogliflozin had genital infections (one of which led to discontinuation) and one patient who received placebo had a urinary tract infection (Table [3](#dom12957-tbl-0003){ref-type="table-wrap"}).

###### 

Safety results

                                                                       Tofogliflozin (N = 140) n (%)   Placebo (N = 70) n (%)
  -------------------------------------------------------------------- ------------------------------- ------------------------
  **Overall summary**                                                                                  
  Any TEAE                                                             95 (67.9)                       49 (70.0)
  Any TEAE possibly related to study treatment                         58 (41.4)                       17 (24.3)
  TEAE leading to death                                                0                               0
  Any serious TEAE                                                     1 (0.7)                         4 (5.7)
  Any serious TEAE possibly related to study treatment                 1 (0.7)                         1 (1.4)
  TEAE leading to permanent treatment discontinuation                  3 (2.1)                         0
  **Individual TEAEs occurring in \>3% of patients in either group**                                   
  Hypoglycaemia                                                        43 (30.7)                       15 (21.4)
  Nasopharyngitis                                                      13 (9.3)                        9 (12.9)
  Thirst                                                               9 (6.4)                         0
  Blood ketones increased                                              5 (3.6)                         2 (2.9)
  Urine output increased                                               5 (3.6)                         0
  Pharyngitis                                                          3 (2.1)                         3 (4.3)
  Influenza                                                            1 (0.7)                         6 (8.6)
  **TEAEs of special interest**                                                                        
  Urinary tract infection                                              0                               1 (1.4)
  Cystitis                                                             0                               1 (1.4)
  Genital infection                                                    1 (0.7)                         0
  Vaginal infection                                                    1 (0.7)                         0
  Skin and subcutaneous tissue disorders                               8 (5.7)                         2 (2.9)
  Asteatotic eczema                                                    3 (2.1)                         0
  Rash                                                                 2 (1.4)                         0
  Cold urticaria                                                       1 (0.7)                         0
  Dyshidrotic eczema                                                   1 (0.7)                         0
  Eczema                                                               1 (0.7)                         0
  Prurigo                                                              1 (0.7)                         0
  Dermatitis contact                                                   0                               2 (2.9)
  Excessive urination                                                  10 (7.1)                        0
  Urine output increased                                               5 (3.6)                         0
  Pollakiuria                                                          3 (2.1)                         0
  Nocturia                                                             1 (0.7)                         0
  Polyuria                                                             1 (0.7)                         0
  AEs related to volume depletion                                      11 (7.9)                        2 (2.9)
  Thirst                                                               9 (6.4)                         0
  Constipation                                                         3 (2.1)                         0
  Cerebellar infarction                                                0                               1 (1.4)
  Lacunar infarction                                                   0                               1 (1.4)
  **Hypoglycaemia**                                                                                    
  Any hypoglycaemia (per protocol)                                     44 (31.4)                       15 (21.4)
  Severe hypoglycaemia                                                 2 (1.4)                         0
  Hypoglycaemic unconsciousness                                        1 (0.7)                         0
  Documented symptomatic hypoglycaemia                                 26 (18.6)                       9 (12.9)
  Plasma glucose \<3.0 mmol/L (54 mg/dL)                               10 (7.1)                        6 (8.6)
  Asymptomatic hypoglycaemia                                           13 (9.3)                        4 (5.7)
  Plasma glucose \<3.0 mmol/L (54 mg/dL)                               3 (2.1)                         1 (1.4)
  Probable symptomatic hypoglycaemia                                   11 (7.9)                        2 (2.9)
  Nocturnal hypoglycaemia                                              12 (8.6)                        3 (4.3)
  Daytime hypoglycaemia                                                41 (29.3)                       14 (20.0)

### 3.3.2. Hypoglycaemia {#dom12957-sec-0022}

The overall frequencies of any hypoglycaemia (44 patients \[31.4%\] for tofogliflozin and 15 patients \[21.4%\] for placebo), documented symptomatic hypoglycaemia (26 patients \[18.6%\] for tofogliflozin and 9 patients \[12.9%\] for placebo), asymptomatic hypoglycaemia (13 patients \[9.3%\] for tofogliflozin and 4 patients \[5.7%\] for placebo) and both nocturnal (12 patients \[8.6%\] for tofogliflozin and 3 patients \[4.3%\] for placebo) and daytime hypoglycaemia (41 patients \[29.3%\] for tofogliflozin and 14 patients \[20.0%\] for placebo) were all numerically higher in patients who received tofogliflozin vs placebo (Table [3](#dom12957-tbl-0003){ref-type="table-wrap"}).

### 3.3.3. TEAEs of special interest {#dom12957-sec-0023}

The overall frequencies of patients experiencing TEAEs of special interest was 62 patients (44.3%) for tofogliflozin and 10 patients (14.3%) for placebo (Table [3](#dom12957-tbl-0003){ref-type="table-wrap"}). Skin and subcutaneous tissue disorders (8 patients \[5.7%\] for tofogliflozin and 2 patients \[2.9%\] for placebo), asteatotic eczema (3 patients \[2.1%\] for tofogliflozin and 0 patients \[0.0%\] for placebo), excessive urination (10 patients \[7.1%\] for tofogliflozin and 0 patients \[0.0%\] for placebo), increased urine output (5 patients \[3.6%\] for tofogliflozin and 0 patients \[0.0%\] for placebo), pollakiuria (3 patients \[2.1%\] for tofogliflozin and 0 patients \[0.0%\] for placebo), AEs related to volume depletion (11 patients \[7.9%\] for tofogliflozin and 2 patients \[2.9%\] for placebo), thirst (9 patients \[6.4%\] for tofogliflozin and 0 patients \[0.0%\] for placebo) and constipation (3 patients \[2.1%\] for tofogliflozin and 0 patients \[0.0%\] for placebo) were all numerically higher in patients who received tofogliflozin vs placebo. Urinary tract infection was experienced by 1 patient in the placebo group (vs 0 patients in the tofogliflozin group) and genital infection was experienced by 1 patient in the tofogliflozin group (vs 0 patients in the placebo group).

### 3.3.4. Clinical laboratory evaluations and vital signs {#dom12957-sec-0024}

There were few potentially clinically significant abnormalities in clinical laboratory values for either treatment group and none for post‐baseline vital signs. Evaluation of lipid profiles indicated no significant differences between treatment groups for total cholesterol, LDL cholesterol, HDL cholesterol or triglycerides (Table [2](#dom12957-tbl-0002){ref-type="table-wrap"}). Compared with placebo, from baseline to week 16 tofogliflozin treatment increased total cholesterol (LS mean difference of 1.80 mg/dL), HDL cholesterol (LS mean difference 2.7 mg/dL), LDL cholesterol (LS mean difference of 1.6 mg/dL) and triglycerides (LS mean difference 10.1 mg/dL).

4. DISCUSSION {#dom12957-sec-0025}
=============

This randomized trial showed that administering tofogliflozin for 16 weeks in Japanese patients with T2DM who were receiving insulin therapy alone or basal insulin plus a DPP‐4 inhibitor but had poor glycaemic control, resulted in a significant reduction in HbA1c compared with placebo, along with significant reductions in FPG, PPG, diastolic BP, body weight and uric acid levels. These benefits were observed despite the fact that patients in the tofogliflozin group were older and had a longer mean duration of disease compared with those who received placebo. They were also less likely to be receiving a DPP‐4 inhibitor as part of their treatment regimen. It should also be noted that patients in both treatment groups had elevated LDL cholesterol concentrations at baseline and that those in the tofogliflozin group also had elevated triglyceride levels.[14](#dom12957-bib-0014){ref-type="ref"}

Subgroup analyses indicated that addition of tofogliflozin was significantly superior to placebo regardless of age, gender, BMI, baseline HbA1c or differences in renal function at baseline. AEs observed with SGLT2 inhibitors,[15](#dom12957-bib-0015){ref-type="ref"}, [16](#dom12957-bib-0016){ref-type="ref"} including hypoglycaemia, increased urine output, thirst and urinary tract/genital infection events, all occurred more frequently with tofogliflozin than with placebo.

The improved glycaemic control (reflected by decreased HbA1c, FPG and PPG) observed with tofogliflozin over 16 weeks of treatment was similar to that observed in previous studies in which other SGLT2 inhibitors were added to treatment for patients with T2DM not adequately controlled on insulin treatment alone or on insulin plus other oral antidiabetic drugs.[15](#dom12957-bib-0015){ref-type="ref"}, [17](#dom12957-bib-0017){ref-type="ref"}, [18](#dom12957-bib-0018){ref-type="ref"}, [19](#dom12957-bib-0019){ref-type="ref"} Addition of tofogliflozin to treatment resulted in significant reductions in HbA1c and achievement of HbA1c \<7% or ≤6.5% in some patients. The mean baseline HbA1c for patients treated with tofogliflozin was high (8.53%) and a tofogliflozin dose of 20 mg/d has been shown to lower HbA1c by −1.02% when administered as monotherapy in patients with T2DM not controlled on diet and exercise alone.[13](#dom12957-bib-0013){ref-type="ref"} These results would suggest that the addition of tofogliflozin to insulin or insulin plus a DPP‐4 inhibitor in the present study would not result in a large percentage of patients achieving aggressive HbA1c targets of \<7%. The similarity between the HbA1c reductions with tofogliflozin monotherapy and when added to insulin is consistent with the independent mechanisms of action for these two antidiabetic treatments.[20](#dom12957-bib-0020){ref-type="ref"} The improved glyaemic control observed in the present study is similar to that observed in other studies investigating the addition of an SGLT2 inhibitor to insulin treatment in Japanese patients.[21](#dom12957-bib-0021){ref-type="ref"}, [22](#dom12957-bib-0022){ref-type="ref"}, [23](#dom12957-bib-0023){ref-type="ref"} Canagliflozin, ipragliflozin and dapagliflozin have all demonstrated greater reductions in HbA1c levels from baseline to 16 weeks when compared with placebo.[21](#dom12957-bib-0021){ref-type="ref"}, [22](#dom12957-bib-0022){ref-type="ref"}, [23](#dom12957-bib-0023){ref-type="ref"}

It has been shown that SGLT2 inhibitors act in the kidney by increasing urinary excretion of glucose; therefore, patients with renal impairment may experience reduced efficacy in terms of Hb1Ac during treatment with SGLT2 inhibitors, particularly those with moderate to severe renal impairment.[24](#dom12957-bib-0024){ref-type="ref"} Dapogliflozin, empagliflozin and ipragliflozin each demonstrated reduced Hb1Ac efficacy in patients with moderate or severe chronic kidney disease.[24](#dom12957-bib-0024){ref-type="ref"}

Addition of tofogliflozin to insulin treatment also significantly lowered both FPG and PPG compared with addition of placebo. The effects of tofogliflozin on FPG are consistent with those reported for other SGLT2 inhibitors when added to insulin.[15](#dom12957-bib-0015){ref-type="ref"}, [18](#dom12957-bib-0018){ref-type="ref"}, [21](#dom12957-bib-0021){ref-type="ref"}, [22](#dom12957-bib-0022){ref-type="ref"}, [23](#dom12957-bib-0023){ref-type="ref"} Other SGLT2 inhibitors have also been shown to reduce PPG.[25](#dom12957-bib-0025){ref-type="ref"}, [26](#dom12957-bib-0026){ref-type="ref"}, [27](#dom12957-bib-0027){ref-type="ref"} A study investigating the addition of dapagliflozin to insulin therapy in Japanese patients also demonstrated a significant reduction from baseline in PPG in the treatment group.[22](#dom12957-bib-0022){ref-type="ref"} The ability of tofogliflozin to lower PPG is important because PPG has been shown to be an independent risk factor for macrovascular disease in patients with diabetes.[28](#dom12957-bib-0028){ref-type="ref"}

Consistent with other studies, the addition of tofogliflozin to insulin therapy significantly decreased body weight by −1.34 kg vs a slight (0.03 kg) increase with placebo.[21](#dom12957-bib-0021){ref-type="ref"}, [22](#dom12957-bib-0022){ref-type="ref"}, [23](#dom12957-bib-0023){ref-type="ref"} Weight change may be attributable to a combination of calorie loss in urine and osmotic diureseis. Weight control is an important consideration in the overall management of T2DM and it has been estimated that each −1% reduction in HbA1c achieved with insulin treatment is associated with an \~2 kg increase in body weight over 1 year of therapy.[29](#dom12957-bib-0029){ref-type="ref"} Weight gain may worsen insulin resistance,[30](#dom12957-bib-0030){ref-type="ref"} resulting in the need for higher insulin doses. Addition of other SGLT2 inhibitors to treatment has also been shown to decrease insulin dose requirements in patients with T2DM.[15](#dom12957-bib-0015){ref-type="ref"}, [31](#dom12957-bib-0031){ref-type="ref"}

Tofogliflozin also significantly reduced diastolic BP by −2.9 mm Hg, as well as decreased systolic BP by −2.2 mm Hg, although this decrease was not statistically significant. Reductions in systolic and diastolic BP were also observed when tofogliflozin was administered as monotherapy to patients with T2DM[13](#dom12957-bib-0013){ref-type="ref"} and when other SGLT2 inhibitors were added to insulin therapy.[15](#dom12957-bib-0015){ref-type="ref"}, [19](#dom12957-bib-0019){ref-type="ref"} The reductions in BP observed with SGLT2 inhibitors are believed to be attributable to a combination of factors, including osmotic diuresis, natriuresis, weight loss and possible effects of improved endothelial nitric oxide release as a result of better glycaemic control.[32](#dom12957-bib-0032){ref-type="ref"} A recent meta‐analysis of clinical trial results for SGLT2 inhibitors has indicated that these agents significantly reduced the risks of all‐cause mortality, cardiovascular death, myocardial infarction and heart failure.[33](#dom12957-bib-0033){ref-type="ref"} Results from the EMPA‐REG OUTCOME study indicated that patients with T2DM at high risk of cardiovascular events who received empagliflozin had a lower rate of the primary composite cardiovascular outcome and of death from any cause compared with placebo when this SGLT2 inhibitor was added to standard care.[34](#dom12957-bib-0034){ref-type="ref"} It was suggested that multiple mechanisms may have contributed to this benefit of SGLT2 inhibition, including reduced arterial stiffness, improved cardiac function and lower myocardial oxygen demand, improvement in renal function, and lowering of uric acid, as well as improved glycaemic control, decreased adiposity and lower blood pressure.[34](#dom12957-bib-0034){ref-type="ref"}

The addition of tofogliflozin to insulin therapy had no significant effects on the plasma lipid profile, which is consistent with long‐term safety data.[13](#dom12957-bib-0013){ref-type="ref"} In a 52‐week safety study investigating tofogliflozin 20 mg as an add‐on therapy to various antidiabetic drugs, triglycerides and LDL cholesterol were not significantly changed compared with baseline. Canagliflozin has been reported to increase LDL cholesterol in a dose‐dependent manner, so it may be prudent to closely monitor lipid profiles in clinical practice.[13](#dom12957-bib-0013){ref-type="ref"} Tofogliflozin significantly decreased uric acid levels. Elevated uric acid levels have been shown to be a significant risk factor for cardiovascular and renal disease, stroke and all‐cause mortality.[35](#dom12957-bib-0035){ref-type="ref"}, [36](#dom12957-bib-0036){ref-type="ref"}

Hypoglycaemia was the most frequently reported TEAE in both treatment groups. In the present study, the frequency of hypoglycaemia associated with tofogliflozin was higher (\~30.0%) than that when tofogliflozin was administered as monotherapy (0% for a 20‐mg dose).[13](#dom12957-bib-0013){ref-type="ref"} The increased risk of hypoglycaemia when tofogliflozin was administered with insulin is consistent with results for other SGLT2 inhibitors[15](#dom12957-bib-0015){ref-type="ref"}, [18](#dom12957-bib-0018){ref-type="ref"}, [19](#dom12957-bib-0019){ref-type="ref"}, [37](#dom12957-bib-0037){ref-type="ref"}, [38](#dom12957-bib-0038){ref-type="ref"}, [39](#dom12957-bib-0039){ref-type="ref"}, [40](#dom12957-bib-0040){ref-type="ref"} and with results for other SLGT2 inhibitors in Japanese patients.[21](#dom12957-bib-0021){ref-type="ref"}, [22](#dom12957-bib-0022){ref-type="ref"}, [23](#dom12957-bib-0023){ref-type="ref"} It is important to note that the insulin dose in the present study could only be changed if FPG was ≥240 mg/dL or patients experienced hypoglycaemia. It is reasonable to suggest that the frequency of hypoglycaemia should decline when patients are permitted to adjust insulin dosing after the addition of tofogliflozin. This suggestion is consistent with results from a previous study, which showed that addition of tofogliflozin to insulin therapy in patients with poor glycaemic control significantly decreased insulin therapy, permitting a reduction in the daily insulin dose.[41](#dom12957-bib-0041){ref-type="ref"} Safety results indicated that \<2% of patients treated with tofogliflozin had genital or urinary tract infections and that 7.1% had excessive urination. Both of these AEs have been associated with administration of SGLT2 inhibitors in previous studies.[8](#dom12957-bib-0008){ref-type="ref"}, [16](#dom12957-bib-0016){ref-type="ref"}, [41](#dom12957-bib-0041){ref-type="ref"} There were no reports of volume depletion with tofogliflozin in the present study or when it was administered as monotherapy.[13](#dom12957-bib-0013){ref-type="ref"} Patients treated with tofogliflozin reported more AEs related to volume depletion than placebo (7.9% vs 2.9%); however, none led to study discontinuation. In previous studies investigating SGLT2 inhibitors, AEs related to volume depletion have been reported as being higher in the study group compared with the placebo or control group.[8](#dom12957-bib-0008){ref-type="ref"}, [16](#dom12957-bib-0016){ref-type="ref"}, [41](#dom12957-bib-0041){ref-type="ref"} Patients may be required to maintain adequate fluid intake in these instances.[8](#dom12957-bib-0008){ref-type="ref"} Previously, it has been speculated this difference may be attributable to patients receiving diuretics.[8](#dom12957-bib-0008){ref-type="ref"}

It is important to note that the findings of the present study are limited by the short 16‐week duration. This period is not sufficient for assessment of the long‐term safety of tofogliflozin. The 36‐week extension phase will provide safety data to fill this important gap out to 52 weeks of treatment. There were differences between groups for age, duration of disease, neuropathy and whether or not a DPP‐4 inhibitor was part of the treatment regimen. Assessment of patients aged ≥65 years and \<65 years as part of the subgroup analysis indicated that age did not have an impact on efficacy in terms of HbA1c reduction.

In conclusion, the results from this 16‐week double‐blind period indicate that addition of tofogliflozin is an effective treatment option for patients with T2DM whose blood glucose is poorly controlled with insulin therapy or with basal insulin combined with a DPP‐4 inhibitor. Overall, tofogliflozin demonstrated an acceptable safety profile; an increased risk of hypoglycaemia was observed, but insulin reduction was not permitted during the present study.
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